Advertisement

Treatment and Prophylaxis of Opportunistic Parasitic Intestinal Infections in HIV-Infected Patients

  • Francis Derouin
  • Jean-Pierre Gangneux

Abstract

In the last 20 years, continuous progress in the treat- ment and prophylaxis of opportunistic infections has resulted in improvement of the quality and duration of life of HIV-infected patients. For most parasitic and fungal infections, there are consensual recom- mendations for treatment regimens of an acute episode and primary and secondary prophylaxis. Indeed, the introduction of highly active antiretrovi- ral therapy (HAART) has dramatically changed the pattern and incidence of opportunistic infections through restoration of immune functions and CD4 cell counts [1–5]. Thus, it has become clear that life- long chemoprophylaxis is not necessary and can be stopped in patients with sustained CD4 levels and improved immunity.

Keywords

Human Immunodeficiency Virus Human Immunodeficiency Virus Infection Opportunistic Infection Clin Infect Visceral Leishmaniasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ledergerber B, Egger M, Erard V, et al(1999) AIDS-related opportunistic illnesses occurring after initia-tion of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999 282:2220–2226CrossRefGoogle Scholar
  2. 2.
    Abgrall S, Rabaud C, Costagliola D, Clinical Epidemi-ology Group of the French Hospital Database on HIV (2001) Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. Clin Infect Dis 33:1747–1755CrossRefPubMedGoogle Scholar
  3. 3.
    US Public Health Service (USPHS) and Infectious Society of America (IDSA) (2000) USPHS/IDSA Pre-vention of Opportunistic Infections Working group. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Clin Infect Dis 30:829–65Google Scholar
  4. 4.
    USPHS/IDSA Prevention of opportunistic Infections Working group (2001) 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in per-sons infected with human immunodeficiency virus http://www.hivatis.org/guidelines/other/OIs/OIGNov 27.pdf
  5. 5.
    Carr A, Mariott D, Field A, Vasak E, Cooper DA (1998) Treatment of HIV-i-associated microsporidio-sis and cryptosporidiosis with combination antiretro-viral therapy. Lancet 351:256–261CrossRefPubMedGoogle Scholar
  6. 6.
    Conteas CN, Berlin OGW, Speck CE, Pandhumas SS, Lariviere MJ, Fu C (1998) Modification of the clinical course of intestinal microsporidiosis in acquired immunodeficiency syndrome patients by immune status and anti-human immunodeficiency virus ther-apy. Am J Trop Med Hyg 58:555–558PubMedGoogle Scholar
  7. 7.
    Le Moing V, Bissuel F, Costagliola D, Eid Z, Chapuis F, Molina JM, Salmon-Ceron D, Brasseur P, Leport C (1998) Decreased prevalence of intestinal cryp-tosporidiosis in HIV-infected patients concomitant to the widespread use of protease inhibitors. AIDS 12:1395–1397CrossRefPubMedGoogle Scholar
  8. 8.
    Goguel J, Katlama C, Sarfati C, Maslo C, Leport C Molina JM (1997) Remission of AIDS associated intes-tinal microsporidiosis with highly active antiretrovi-ral therapy. AIDS 11:1658–1659PubMedGoogle Scholar
  9. 9.
    Maggi P, Larocca AM, Quarto M, Serio G, Brandon-isio O, Angarano G, Pastore G (2000) Effect of anti-retroviral therapy on cryptosporidiosis and microsporidiosis in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis 19:213–217CrossRefPubMedGoogle Scholar
  10. 10.
    Schmidt W, Wahnschaffe U, Schafer M, Zippel T, Arvand M, Meyerhans A, Riecken EO, Ullrich R (2001) Rapid increase of mucosal CD4 T cells followed by clearance of intestinal cryptosporidiosis in an AIDS patient receiving highly active antiretroviral therapy. Gastroenterology 120:984–987CrossRefPubMedGoogle Scholar
  11. 11.
    Hewitt RG, Yiannoutsos CT, Higgs ES, et al(2000) Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trial Group. Clin Infect Dis 31:1084–1092CrossRefPubMedGoogle Scholar
  12. 12.
    Gilles HM, Hoffman PS (2002) Treatment of intestin-al parasitic infections: a review of nitazoxanide. Trends Parasitol 18:95–97CrossRefPubMedGoogle Scholar
  13. 13.
    Rossignol JF, Ayoub A, Ayers MS (2001) Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-con-trolled study of Nitazoxanide. J Infect Dis 184:103–106CrossRefPubMedGoogle Scholar
  14. 14.
    Rossignol JF, Hidalgo H, Feregrino M, Higuera F, Gomez WH, Romero JL, Padierna J, Geyne A, Ayers MS (1998) A double-’blind’ placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans R Soc Trop Med Hyg 92:663–666CrossRefPubMedGoogle Scholar
  15. 15.
    Doumbo O, Rossignol JF, Pichard E, Traore HA, Dembele TM, Diakite M, Traore F, Diallo DA (1997) Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syn-drome in tropical Africa. Am J Trop Med Hyg 56:637–639PubMedGoogle Scholar
  16. 16.
    Uip DE, Lima ALL, Amato VS, Boulos M, Neto VA, Bern David D (1998) Roxythromycin treatment for diarrhoea caused by Cryptosporidium spp. in patients with AIDS. J Antimicrob Chemother 41: 93–97CrossRefPubMedGoogle Scholar
  17. 17.
    Sprinz E, Mailman R, Barcellos S, Silbert S, Scheatatsky G, Bern David D (1998) AIDS-related cryptosporidial diarrhoae: an open study with rox-ythromycin. J Antimicrob Chemother 41:S85-91Google Scholar
  18. 18.
    Dionisio D, Orsi A, Sterrantino G, Meli M, Di Lollo S, Ibba Manneschi L, Trotta M, Pozzi M, Sani L, Leoncini F (1998) Chronic cryptosporidiosis in patients with AIDS: stable remission and possible eradication after long-term, low dose azithromycin. J Clin Pathol 51:138–12CrossRefPubMedGoogle Scholar
  19. 19.
    Smith NH, Cron S, Valdez LM, Chappell CL, White AC Jr (1998) Combination drug therapy for cryp-tosporidiosis in AIDS. J Infect Dis 178:900–903CrossRefPubMedGoogle Scholar
  20. 20.
    Fichtenbaum CJ, Zackin R, Feinberg J, Benson C, Griffiths JK, AIDS Clinical trials group New York con-cept sheet team 064 (2000) Rifabutin but not clar-ithromycin prevents cryptosporidiosis in persons with advanced HIV infection. AIDS 14:2889–2893CrossRefPubMedGoogle Scholar
  21. 21.
    Holmberg SD, Moorman AC, Von Bargen JC, Palella FJ, Loveless MO, Ward DJ (1998) Possible effective-ness of clarithromycin and rifabutin for cryp-tosporidiosis chemoprophylaxis in HIV disease. JAMA 279:384–386CrossRefPubMedGoogle Scholar
  22. 22.
    Molina JM, Chastang C, Goguel J, Michiels JF, Sarfati C, Desportes-Livage I, Horton J, Derouin F, Modai J (1998) Albendazole for treatment and prophylaxis of microsporidiosis due to Encephalitozoon intestinalis in patients with AIDS: a randomized double-blind controlled trial. J Inf Dis 177:1373–1377CrossRefGoogle Scholar
  23. 23.
    Katiyar SK, Edlind TD (1997) In vitro susceptibilities of the AIDS-associated microsporidian Encephalito-zoon intestinalis to albendazole, its sulfoxide metabo-lite, and 12 additional benzimidazole derivatives. Antimicrob Agents Chemother 41:2729–2732PubMedGoogle Scholar
  24. 24.
    Molina JM, Goguel J, Sarfati C, Chastang C, Desportes-Livage I, Michiels JF, Maslo C, Katlama C, Cotte L, Leport C, Raffi F, Derouin F, Modai” J for the French Microsporidiosis Study Group (1997) Poten-tial efficacy of fumagillin in intestinal microsporidio-sis due to Enterocytozoon bieneusi in patients with HIV infection: results of a drug screening study. AIDS 11:1603–1610CrossRefPubMedGoogle Scholar
  25. 25.
    Molina JM, Goguel J, Sarfati C, et al(2000) Trial of oral fumagillin for the treatment of intestinal microsporidiosis in patients with HIV-infection. AIDS 14:1341–1348CrossRefPubMedGoogle Scholar
  26. 26.
    Molina JM, Tourneur M, Sarfati C, Chevret S, de Gou-vello A, Gobert JG, Balkan S, Derouin F (2002) Fumagillin treatment of intestinal microsporidiosis. N Engl J Med 346:1963–1969CrossRefPubMedGoogle Scholar
  27. 27.
    Dionisio D, Ibba Manneschi L, Di Lollo S, Orsi A, Sterrantino G, Meli M, Gabbrielli M, Tani A, Papucci A, Leoncini F (1997) Enterocytozoon bieneusi in AIDS: symptomatic relief and parasite changes after fura-zolidone. J Clin Path 50:472–476CrossRefPubMedGoogle Scholar
  28. 28.
    Bicart-See A, Massip P, Linas MD, Datry A (2000) Successful treatment with nitazoxanide of Enterocyto-zoon bieneusi microsporidiosis in a patient with AIDS. Antimicrob Agents Chemother 44:167–168CrossRefPubMedGoogle Scholar
  29. 29.
    Anwar-Bruni DM, Hogan SE, Schwartz DA, Wilcox CM, Bryan RT, Lennox JL (1996) Atovaquone is effec-tive treatment for the symptoms of gastrointestinal microsporidiosis in HIV-i infected patients. AIDS 10:619–623CrossRefPubMedGoogle Scholar
  30. 30.
    Coyle C, Kent M, Tanowitz HB, Wittner M, Weiss LM (1998) TNP-470 is an effective antimicrosporidial agent. J Infect Dis 177:515–518CrossRefPubMedGoogle Scholar
  31. 31.
    Dowd SE, Gerba CP, Pepper IL (1998) Confirmation of the human-pathogenic microsporidia Enterocytozoon bieneusi, Encephalitozoon intestinalis, and Vittafor-ma corneae in water. Appl Environ Microbiol 64:3332–3335PubMedGoogle Scholar
  32. 32.
    Sparfel JM, Sarfati C, Liguory O, Caroff B, Dumoutier N, Gueglio B, Billaud E, Raffi F, Molina JM, Miegeville M, Derouin F (1997) Detection of microsporidia and identification of Enterocytozoon bieneusi in surface water by filtration followed by specific PCR. J Eukary-ot Microbiol 44:78SCrossRefGoogle Scholar
  33. 33.
    Hutin Y, Sombardier MN, Liguory O, Sarfati C, Der-ouin F, Modai’ J, Molina JM (1998) Risk factors for intestinal microsporidiosis in patients with human immunodeficiency virus infection: a case-control study. J Infect Dis 178:904–907CrossRefPubMedGoogle Scholar
  34. 34.
    Pape JW, Verdier RI, Johnson WD Jr (1989) Treat-ment and prophylaxis of Isospora belli infection in patients with the acquired immunodeficiency syn-drome. N Engl J Med 320:1044–1047CrossRefPubMedGoogle Scholar
  35. 35.
    DeHovitz JA, Pape JW, Boncy M, Johnson WD Jr (1986) Clinical manifestations and therapy of Isospora belli infection in patients with the acquired immun-odeficiency syndrome. N Engl J Med 315:87–90CrossRefPubMedGoogle Scholar
  36. 36.
    Verdier RI, Fitzgerald DW, Johnson WD Jr, Pape JW (2000) Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. Ann Intern Med 132:885–888PubMedGoogle Scholar
  37. 37.
    Weiss LM, Perlman DC, Sherman J, Tanowitz H, Wit-tner M (1988) Isospora belli infection: treatment with pyrimethamine. Ann Intern Med 109:474–475PubMedGoogle Scholar
  38. 38.
    Meyohas MC, Capella F, Poirot JL, Lecomte I, Binet D, Eliaszewicz M, Frottier J (1990) Traitement par doxy-cycline et nifuroxazide de l’infection ä Isospora belli au cours du SID A. Pathol Biol (Paris) 38:589–591Google Scholar
  39. 39.
    Limson-Pobre RN, Merrick S, Gruen D, Soave R (1995) Use of diclazuril for the treatment of isospori-asis in patients with AIDS. Clin Infect Dis 20:201–202CrossRefPubMedGoogle Scholar
  40. 40.
    Kayembe K, Desmet P, Henry MC, Stoffels P (1989) Diclazuril for Isospora belli infection in AIDS. Lancet 8651:1397–1398CrossRefGoogle Scholar
  41. 41.
    Dionisio D, Sterrantino G, Meli M, Leoncini F, Orsi A, Nicoletti P (1996) Treatment of isosporiasis with combined albendazole and ornidazole in patients with AIDS. AIDS 11:1301–1302CrossRefGoogle Scholar
  42. 42.
    Pape JW, Verdier RI, Boncy M, Boncy J, Johnson WD (1994) Cyclospora infection in adults with HIV. Clini-cal manifestations, treatment and prophylaxis. Ann intern Med 121:654–657PubMedGoogle Scholar
  43. 43.
    Deodhar L, Maniar JK, Saple DG (2000) Cyclospora infection in acquired immunodeficiency syndrome. J Assoc Physicians India 48:404–406PubMedGoogle Scholar
  44. 44.
    Ramakrishna BS (1999) Prevalence of intestinal pathogens in HIV patients with diarrhea: implica-tions for treatment. Indian J Pediatr 66:85–91CrossRefPubMedGoogle Scholar
  45. 45.
    Aronson NE, Cheney C, Rholl V, Burris D, Hadro N (2001) Biliary giardiasis in a patient with human immunodeficiency virus. J Clin Gastroenterol 33:167–170CrossRefPubMedGoogle Scholar
  46. 46.
    Nash TE, Ohl CA, Thomas E, Subramanian G, Keiser P, Moore TA (2001) Treatment of patients with refrac-tory giardiasis. Clin Infect Dis 33:22–28CrossRefPubMedGoogle Scholar
  47. 47.
    Upcroft P, Upcroft JA (2001) Drug targets and mech-anisms of resistance in the anaerobic protozoa. Clin Microbiol Rev 14:150–164CrossRefPubMedGoogle Scholar
  48. 48.
    Upcroft P (1998) Drug resistance in Giardia: clinical versus laboratory isolates. Drug Resist Updates 1:166–168CrossRefGoogle Scholar
  49. 49.
    Lemee V, Zaharia I, Nevez G, Rabodonirina M, Brasseur P, Ballet JJ, Favennec L (2000) Metronida-zole and albendazole susceptibility of 11 clinical iso-lates of Giardia duodenalis from France. J Antimicrob Chemother 46:819–821CrossRefPubMedGoogle Scholar
  50. 50.
    Adagu IS, Nolder D, Warhurst DC, Rossignol JF (2002) In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J Antimicrob Chemother 49:103–111CrossRefPubMedGoogle Scholar
  51. 51.
    Abboud P, Lemee V, Gargala G, Brasseur P, Ballet JJ, Borsa-Lebas F, Caron F, Favennec L (2001) Successful treatment of metronidazole-and albendazole-resist-ant giardiasis with nitazoxanide in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 32:1792–1794CrossRefPubMedGoogle Scholar
  52. 52.
    Lowther SA, Dworkin MS, Hanson DL (2000) Enta-moeba histolytica/Entamoeba dispar infections in human immunodeficiency virus-infected patients in the United States. Clin Infect Dis 30:955–959CrossRefPubMedGoogle Scholar
  53. 53.
    Hung CC, Chen PJ, Hsieh SM, Wong JM, Fang CT, Chang SC, Chen MY (1999) Invasive amoebiasis: an emerging parasitic disease in patients infected with HIV in an area endemic for amoebic infection. AIDS 3:2421–2428CrossRefGoogle Scholar
  54. 54.
    Mitarai S, Nagai H, Satoh K, Hebisawa A, Shishido H (2001) Amebiasis in Japanese homosexual men with human immunodeficiency virus infection. Intern Med 40:671–675CrossRefPubMedGoogle Scholar
  55. 55.
    Liu CJ, Hung CC, Chen MY, Lai YP, Chen PJ, Huang SH, Chen DS (2001) Amebic liver abcess and human immunodeficiency virus infection: a report of three cases. J Clin Gastroenterol 33:64–68CrossRefPubMedGoogle Scholar
  56. 56.
    Guerrant RL, Van Guilder TS, Thielman NM, et al (2001) Practical guideline for the management of infectious diarrhea. Clin Infect Dis 32:331–350CrossRefPubMedGoogle Scholar
  57. 57.
    Rossignol JF, Ayoub A, Ayers MS (2001) Treatment of diarrhea cause by Giardia intestinalis and Enta-moabea histolytica or E. dispar. a randomized double-blind placebo-controlled study of nitazoxanide. J Infect Dis 184:381–384CrossRefPubMedGoogle Scholar
  58. 58.
    Henry MC, De Clercq D, Lokombe B, Kayembe K, Kapita B, Mamba K, Mbendi N, Mazebo P (1986) Par-asitological observations of chronic diarrhoea in sus-pected AIDS adult patients in Kinshasa (Zaire). Trans R Soc Trop Med Hyg 80:309–310CrossRefPubMedGoogle Scholar
  59. 59.
    Garavelli PL, Orsi P, Scaglione L (1988) Blastocystis hominis infection during AIDS. Lancet 10:1364CrossRefGoogle Scholar
  60. 60.
    Brites C, Barberino MG, Bastos MA, Sampaio Sa M, Silva N (1997) Blastocystis hominis as a potential cause of diarrhea in AIDS patients: a report of six cases in Bahia, Brazil. Braz J Infect Dis 1:91–94PubMedGoogle Scholar
  61. 61.
    Albrecht H, Stellbrink HJ, Koperski K, Greten H (1995) Blastocystis hominis in human immunodefi-ciency virus-related diarrhea. Scand J Gastroenterol 30:909–914CrossRefPubMedGoogle Scholar
  62. 62.
    Sarangarajan R, Ranganathan A, Belmonte AH, Tchertkoff V (1997) Strongyloides stercoralis infection in AIDS. AIDS Patient Care STDS 11:407–414CrossRefPubMedGoogle Scholar
  63. 63.
    Ferreira MS, Nishioka Sde A, Borges AS, Costa-Cruz JM, Rossin IR, Rocha A, Silvestre MT, Nunes-Araujo FR (1999) Strongyloidiasis and infection due to human immunodeficiency virus: 25 cases at a Brazil-ian teaching hospital, including seven cases of hyper-infection syndrome. Clin Infect Dis 28:154–155CrossRefPubMedGoogle Scholar
  64. 64.
    Heyworth MF (1996) Parasitic diseases in immuno-compromised hosts. Cryptosporidiosis, isosporiasis, and strongyloidiasis. Gastroenterol Clin North Am 25:691–707CrossRefPubMedGoogle Scholar
  65. 65.
    Cahill KM, Shevchuk M (1996) Fulminant, systemic strongyloidiasis in AIDS. Ann Trop Med Parasitol 90:313–318PubMedGoogle Scholar
  66. 66.
    Celedon JC, Mathur-Wagh U, Fox J, Garcia R, Wiest PM (1994) Systemic strongyloidiasis in patients infected with the human immunodeficiency virus. A report of 3 cases and review of the literature. Medicine (Baltimore) 7:256–63Google Scholar
  67. 67.
    Müller A, Fatkenheuer G, Salzberger B, Schrappe M, Diehl V, Franzen C (1998) Strongyloides stercoralis infection in a patient with AIDS and non-Hodgkin lymphoma. Dtsch Med Wochenschr 27:381–385CrossRefGoogle Scholar
  68. 68.
    Torres JR, Isturiz R, Murilo J, Guzman M, Contreras R (1993) Efficacy of ivermectin in the treatment of strongyloidiasis complicating AIDS. Clin Infect Dis 17:900–902CrossRefPubMedGoogle Scholar
  69. 69.
    Zaha O, Hirata T, Kinjo F, Saito A (2000) Strongy-loidiasis progress in diagnosis and treatment. Intern Med 39:695–700CrossRefPubMedGoogle Scholar
  70. 70.
    Boken DJ, Leoni PA, Preheim LC (1993) Treatment of Strongyloides stercoralis hyperinfection syndrome with thiabendazole administered per rectum. Clin Infect Dis 16:123–126CrossRefPubMedGoogle Scholar
  71. 71.
    Chiodini PL, Reid AJC, Wiselka MJ, Firmin R, Power-aker J (2000) Parenteral ivermectin in Strongyloides hyperinfection. Lancet 355:43–44CrossRefPubMedGoogle Scholar
  72. 72.
    Maynart M, Lievre L, Sow PS, Kony S, Gueye NF, Bassene E, Metro A, Ndoye I, Ba DS, Coulaud JP, Costagliola D (2001) Primary prevention with cotri-moxazole for HIV-i-infected adults: results of the pilot study in Dakar, Senegal. J Acquir Immune Defic Syndr 26:130–136CrossRefPubMedGoogle Scholar
  73. 73.
    Dworkin MS, Williamson J, Jones JL, Kaplan JE. (2001) Prophylaxis with trimethoprim-sulfamethoxa-zole for human immunodeficiency virus-infected patients: impact on risk for infectious diseases. Clin Infect Dis 33:393–398CrossRefPubMedGoogle Scholar
  74. 74.
    Anglaret X, Chene G, Attia A, et al(1999) Early chemotherapy with trimethoprim-sulfamethoxazole for HIV-i infected adults in Abidjan, Cote dTvoire: a randomized trial. Lancet 353:1463–1468CrossRefPubMedGoogle Scholar
  75. 75.
    Kelly P, Lungu F, Keane E, Baggaley R, Kazembe F, Pobee J, Farthing M (1996) Albendazole chemothera-py for treatment of diarrhoea in patients with AIDS in Zambia: a randomized double blind controlled trial. BMJ 312:1187–1191CrossRefPubMedGoogle Scholar
  76. 76.
    Suzuki Y, Sher A, Yap G, Park D, Neyer LE, Liesenfeld O, Fort M, Kang H, Gufwoli E (2000) IL-10 is required for prevention of necrosis in the small intestine and mortality in both genetically resistant BALB/c and susceptible C57BL/6 mice following peroral infection with Toxoplasma gondii. J Immunol 164:5375–5382PubMedGoogle Scholar
  77. 77.
    Couvreur J, Leport C (1998) Toxoplasma gondii. In: Yu VL, Merignac TC, Barriere SL (eds) Antimicrobial therapy and vaccines. Williams & Wilkins, Paris, pp 600–612Google Scholar
  78. 78.
    Torre D, Casari S, Speranza F, et al(1998) Random-ized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplas-mic encephalitis in patients with AIDS. Antimicrob Agents Chemother 42:1346–1349PubMedGoogle Scholar
  79. 79.
    Torre D, Speranza F, Martegani R, Zeroli C, Banfi M, Airoldi M (1998) A retrospective study of treatment of cerebral toxoplasmosis in AIDS patients with trimethoprim-sulphamethoxazole. J Infect 37:15–18CrossRefPubMedGoogle Scholar
  80. 80.
    Torres RA, Weinberg W, Stansell J, Leoung G, Kovacs J, Rogers M, Scott J, the Atovaquone/Toxoplasmic encephalitis study group (1997) Atovaquone for sal-vage treatment and suppression of toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 24:422–429CrossRefPubMedGoogle Scholar
  81. 81.
    Kirk O, Lundgren JD, Pedersen C, Nielsen H, Gerstoft J (1999) Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy? AIDS 13:1647–1651CrossRefPubMedGoogle Scholar
  82. 82.
    Soriano V, Dona C, Rodriguez-Rosado R, Barreiro P, Gonzalez-Lahoz J (2000) Discontinuation of second-ary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 14:383–386CrossRefPubMedGoogle Scholar
  83. 83.
    BeTanger F, Derouin F, Grangeot-Keros L, Meyer L (1999) Incidence and risk factors of toxoplasmosis in a cohort of human immunodeficiency virus-infected patients: 1988-1995. Clin Infect dis 28:575–581CrossRefGoogle Scholar
  84. 84.
    Leport C, Franck J, Chene G, Derouin F, Ecobichon JL, Pueyo S, Miro JM, Luft BJ, Morlat P, Dumon H (2001) Immunoblot profile as predictor of toxoplas-mic encephalitis in patients infected with human immunodeficiency virus. Clin Diagn Lab Immunol 8:579–584PubMedGoogle Scholar
  85. 85.
    Mussini C, Pezzotti P, Govoni A, et al(2000) Discon-tinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study. J Infect Dis 2000 181:1635–1642CrossRefGoogle Scholar
  86. 86.
    Furrer H, Opravil M, Bernasconi E, Telenti A, Egger M (2000) Stopping primary prophylaxis in HIV-i-infect-ed patients at high risk of Toxoplasma encephalitis. Swiss HIV Cohort Study. Lancet 355:2217–2218CrossRefPubMedGoogle Scholar
  87. 87.
    Furrer H, Egger M, Opravil M, et al(1999) Discontin-uation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-i-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med 340:1301–1306CrossRefPubMedGoogle Scholar
  88. 88.
    Fournier S, Rabian C, Alberti C, Carmagnat MV, Garin JF, Charron D, Derouin F, Molina JM (2001) Immune recovery under highly active antiretroviral therapy is associated with restoration of lymphocyte proliferation and interferon-gamma production in the presence of Toxoplasma gondii antigens. J Infect Dis 183:1586–1591CrossRefPubMedGoogle Scholar
  89. 89.
    Alvar J, Canavate C, Gutierrez-Solar B, Jiminez M, Laguna F, Lopez-Velez R, Molina R, Moreno J (1997) Leishmania and human immunodeficiency virus co-infection: the first 10 years. Clin Microbiol Rev 10:298–319PubMedGoogle Scholar
  90. 90.
    Weber R, Ledergerber B, Zbinden R, Altwegg M, Pfyf-fer GE, Spycher MA, Briner J, Kaiser L, Opravil M, Meyenberger C, Flepp M (1999) Enteric infections and diarrhea in human immunodeficiency virus-infected persons. Arch Intern Med 159:1473–1480CrossRefPubMedGoogle Scholar
  91. 91.
    Rosenthal E, Marty P, del Giudice P, Pradier C, Ceppi C, Gastaut JA, Le Fichoux X, Cassuto JP (2000) HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania. Clin Infect Dis 31:1093–1095CrossRefPubMedGoogle Scholar
  92. 92.
    Farault-Gambarelli F, Piarroux R, Deniau M, Giu-siano B, Marty P, Michel G, Faugere B, Dumon H (1997) In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishma-niasis. Antimicrobiol Agents Chemother 41:827–830Google Scholar
  93. 93.
    Croft SL, Davidson RNN, Thornton EA (1991) Liposo-mal amphotericin B in the treatment of visceral leish-maniasis. J Antimicrobiol Chemother 28:S111–S118CrossRefGoogle Scholar
  94. 94.
    Gangneux JP, Sulahian A, Garin JF, Derouin F (1996) Therapy of visceral leishmaniasis due to Leishmania infantum: Experimental assessment of the efficacy of AmBisome. Antimicrobiol Agent Chemother 40:214–1218Google Scholar
  95. 95.
    Jha TK, Sundar S, Thakur CP, Bachmann P, Karb-wang J, Fischer C, Voss A, Berman J (1999) Miltefos-ine, an oral agent, for the treatment of indian visceral leishmaniasis. N Engl J Med 341:1795–2000CrossRefPubMedGoogle Scholar
  96. 96.
    Sundar S, Makharia A, More DK, Agrawal G, Voss A, Fischer C, Bachmann P, Murray HW (2000) Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis 31:1113–1114CrossRefGoogle Scholar
  97. 97.
    Soto J, Toledo J, Gutierrez P, Nicholls RS, Padilla J, Engel J, Fischer C, Voss A, Berman J (2001) Treatment of american cutaneous leishmaniasis with miltefos-ine, an oral agent. Clin Infect Dis 33:E57-61Google Scholar
  98. 98.
    Fisher C, Engel K, Bommer W. Treatment of VL/HIV co-infected patients with oral miltefosine. Satellite symposium at the World Leish II Congress, Hersonis-sos, Crete, 2001. Abstract, p 21Google Scholar
  99. 99.
    Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dis-mukes WE, Edwards JE (2000) Practice guidelines for the treatment of candidiasis. Clin Infect Dis 30:662–78CrossRefPubMedGoogle Scholar
  100. 100.
    Reef SE, Mayer KH (1995) Opportunistic candidal infections in patients infected with human immunod-eficiency virus: prevention issues and priorities. Clin Infect Dis 21:S99-102Google Scholar
  101. 101.
    Masur H, Holmes KK, Kaplan JE (2000) Introduction to the 1999 USPHS/IDSA guidelines for the preven-tion of opportunistic infections in persons infected with human immunodeficiency virus. Clin Infect Dis 3o:S1–S4CrossRefGoogle Scholar
  102. 102.
    Mylonakis E, Flanigan TP (1998) Antifungal prophy-laxis with weekly fluconazole for patients with AIDS. Clin Infect Dis 27:1376–1378CrossRefPubMedGoogle Scholar
  103. 103.
    Pelletier R, Peter J, Antin C, Gonzalez C, Wood L, Walsh TJ (2000) Emergence of resistance of Candida albicans to clotrimazole in human immunodeficiency virus-infected children: in vitro and clinical correla-tions. J Clin Microbiol 38:1563–1568PubMedGoogle Scholar
  104. 104.
    Martinez M, Lopez-Ribot JL, Kirkpatrick WR, Bach-mann SP, Perea S, Ruesga MT, Patterson TF (2002) Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis. J Antimicrob Chemother 49:515–524CrossRefPubMedGoogle Scholar
  105. 105.
    Rex JH, Rinaldi MG, Pfaller MA (1995) Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 39:1–8CrossRefPubMedGoogle Scholar
  106. 106.
    Bierhoff E, Tran A, Pakos E, Rockstroh J, Pfeifer U (1996) Perforation of the small intestine in a patient with diseminated Pneumocystis carinii infection in AIDS. Gen Diagn Pathol 141:255–260PubMedGoogle Scholar
  107. 107.
    Carter TR, Cooper PH, Petri WA Jr, Kim CK, Walzer PD, Guerrant RL (1988) Pneumocystis carinii infec-tion of the small intestine in a patient with acquired immune deficiency syndrome. Am J Clin Pathol 89:679–683PubMedGoogle Scholar
  108. 108.
    Lopez Bernaldo de Quiros JC, Miro JM, Pena JM (2001) A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumo-cystis carinii pneumoniae after highly active anti-retroviral therapy in patients with HIV infection. N Engl J Med 344:159–167CrossRefPubMedGoogle Scholar
  109. 109.
    Ledergerber B, Mocroft A, Reiss P, et al(2001) Dis-continuation of secondary prophylaxis against Pneu-mocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral thera-py. Eight European Study Groups. N Engl J Med 344:168–174CrossRefPubMedGoogle Scholar
  110. 110.
    Kovacs JA, Masur H (2000) Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 342:1416–1429CrossRefPubMedGoogle Scholar
  111. 111.
    Girard PM (2001) Discontinuing Pneumocystis carinii prophylaxis. N Engl J Med 344:22–23CrossRefGoogle Scholar
  112. 112.
    Trikalinos TA, Ioannidis JP (2001) Discontinuation of Pneumocystis carinii prophylaxis in patients infected with human immunodeficiency virus: a meta-analysis and decision analysis. Clin Infect Dis 33:1901–1909CrossRefPubMedGoogle Scholar
  113. 113.
    Van Calck M, Motte S, Rickaert F, Serruys E, Adler M, Wybran J (1988) Cryptococcal anal ulceration in a patient with AIDS. Am J Gastroenterol 83:1306–1308PubMedGoogle Scholar
  114. 114.
    Saag MA, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, Sobel JD, Dismukes WE (2000) Practrice Guidelines for the management of crypto-coccal disease. Clin Infect Dis 30:710–718CrossRefPubMedGoogle Scholar
  115. 115.
    Sharkey-Mathis PK, Velez J, Fetchick R, Graybill JR (1993) Histoplasmosis in the acquired immunodefi-ciency syndrome: treatment with itraconazole and fluconazole. J AIDS 6:809–819Google Scholar
  116. 116.
    Spivak H, Schlasinger MH, Tabanda-Lichauco R, Fer-stenberg H (1996) Small bowel obstruction from gas-trointestinal histoplasmosis in acquired immune deficiency syndrome. Am Surg 62:369–372PubMedGoogle Scholar
  117. 117.
    Balthazar EJ, Megibow AJ, Barry M, Opulencia JF (1993) Histoplasmosis of the colon in patients with AIDS: imaging findings in four cases. AJR Am J Roentgenol 161:585–587PubMedGoogle Scholar
  118. 118.
    McKinsey DS (1998) Histoplasmosis in AIDS: advances in management. AIDS Patient Care STDS 12:775–781CrossRefPubMedGoogle Scholar
  119. 119.
    Wheat LJ, Connolly P, Smedema M, Brizendine E, Hafner R (2001) Emergence of resistance to flucona-zole as a cause of failure during treatment of histo-plasmosis in patients with acquired immunodeficien-cy disease syndrome. Clin Infect Dis 33:1910–1913CrossRefPubMedGoogle Scholar
  120. 120.
    McNeil MM, Ampel NM (1995) Opportunistic coccid-ioidomycosis in patients infected with human immunodeficiency virus: prevention issues and prior-ities. Clin Infect Dis 21[Suppl 1]:S111-113Google Scholar
  121. 121.
    Singh VR, Smith DK, Lawerence J, Kelly PC, Thomas AR, Spitz B, Sarosi GA (1996) Coccidioidomycosis in patients infected with human immunodeficiency virus: review of 91 cases at a single institution. Clin Infect Dis 23:563–568CrossRefPubMedGoogle Scholar
  122. 122.
    Woods CW, McRill C, Plikaytis BD, Rosenstein NE, Mosley D, Boyd D, England B, Perkins BA, Ampel NM, Hajjeh RA (2000) Coccidioidomycosis in human immunodeficiency virus-infected persons in Arizona, 1994-1997: incidence, risk factors, and prevention. J Infect Dis 181:1428–1434CrossRefPubMedGoogle Scholar
  123. 123.
    Nittayananta W (1999) Penicilliosis marneffei: anoth-er AIDS defining illness in Southeast Asia. Oral Dis 5:286–293CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2003

Authors and Affiliations

  • Francis Derouin
  • Jean-Pierre Gangneux

There are no affiliations available

Personalised recommendations